In studies, how long did Lonsurf increase survival in colorectal cancer?
Medically reviewed by Drugs.com Last updated on Jul 6, 2018.
Official Answerby Drugs.com
In clinical studies, patients treated with Lonsurf lived an average of 7.1 months compared to 5.3 months for those treated with placebo (a sugar pill). On average, the time to cancer progression was two months for patients on Lonsurf compared to 1.7 months for patients receiving placebo.
Lonsurf (trifluridine and tipiracil) is approved for patients with advanced (metastatic) colorectal cancer who are no longer responding to other therapies, such as chemotherapy and biological therapy.
Lonsurf is a nucleoside metabolic inhibitor which is incorporated directly into DNA and interferes with its function. The blood level of trifluridine is maintained by the enzyme inhibitor tipiracil.
Common side effects with Lonsurf include anemia, neutropenia (low white blood cells), thrombocytopenia (low blood platelets), physical weakness, extreme tiredness and lack of energy (fatigue).
Related Medical Questions
- Lonsurf Information for Consumers
- Lonsurf Information for Healthcare Professionals (includes dosage details)
- Side Effects of Lonsurf (detailed)